Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 3/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488433 | 1.00 | HTR1A (0.45) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL255277 | 1.00 | HTR1A (0.45) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL16716869 | 1.00 | HTR1A (0.45) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL5219148 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| Hydrochloric Acid SCHEMBL18424980 | 0.98 | HTR1A (0.44) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL10326492 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL10326687 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL13620120 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL1995891 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 | |
| SCHEMBL2387767 | 0.98 | CHRM5 (0.46) | HTR1AHTR2AKCNH2HTR1DHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670314-A4 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA INC (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| EP-0873298-A4 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMA INC (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0873298-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | claimed |
| US-5648541-A | FORMING ENANTIOMERS FROM IMINES BY REDUCTION WITH LITHIUM ALUMINUM HYDRIDE | NPS PHARMACEUTICALS, INC. (US) | 1997-07-15 | — | — | US | claimed |
| WO-1997011934-A1 | CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES | NPS PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | claimed |
| JP-2036202-A | — | — | None | — | — | JP | disclosed |
| JP-8301850-A | — | — | None | — | — | JP | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |
| JP-H0236202-A | OPTICALLY ACTIVE POLYMERIZATION CATALYST AND SYNTHESIS OF OPTICALLY ACTIVE POLYMER USING SAME | DAICEL CHEM IND LTD | 1990-02-06 | — | — | JP | disclosed |
| EP-0156191-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1989-07-19 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | HTR1A 2902/4885HTR2A 1534/4885KCNH2 4877/4885 |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | HTR1A 4448/4885HTR2A 4486/4885KCNH2 4292/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | HTR1A 1091/4885HTR2A 2766/4885KCNH2 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.